WS Investor
14 Apr 2026, 20:14
Gilead Sciences Inc. announced expanded global investment in its HIV prevention drug lenacapavir, with support from PEPFAR and The Global Fund to increase access in high-risk, low-resource regions.
The additional commitment aims to provide lenacapavir to up to 1 million more people over the next three years, bringing the total target to 3 million individuals by 2028. The twice-yearly injectable treatment is considered a major breakthrough in HIV prevention and is already being distributed in regions such as sub-Saharan Africa.
Gilead stated it will supply the drug at no profit to these global health programs in the near term, while preparing for a broader rollout through generic manufacturing starting in 2027. The initiative is supported by partnerships with multiple generic drug producers to expand long-term affordability and accessibility.
The move comes as global health organizations continue efforts to reduce the approximately 1.3 million new HIV infections each year, with long-acting prevention therapies seen as a key tool in combating the epidemic.
Business Wire
The additional commitment aims to provide lenacapavir to up to 1 million more people over the next three years, bringing the total target to 3 million individuals by 2028. The twice-yearly injectable treatment is considered a major breakthrough in HIV prevention and is already being distributed in regions such as sub-Saharan Africa.
Gilead stated it will supply the drug at no profit to these global health programs in the near term, while preparing for a broader rollout through generic manufacturing starting in 2027. The initiative is supported by partnerships with multiple generic drug producers to expand long-term affordability and accessibility.
The move comes as global health organizations continue efforts to reduce the approximately 1.3 million new HIV infections each year, with long-acting prevention therapies seen as a key tool in combating the epidemic.
Business Wire